REYKJAVIK - Alvotech (NASDAQ: ALVO), an international biopharmaceutical firm, announced the appointment of Christina Siniscalchi as its interim Chief Quality Officer. Siniscalchi, with a decade of experience in senior quality roles at Alvogen, succeeds Sandra Casaca amid organizational changes.
Siniscalchi brings over 25 years of U.S. pharmaceutical industry expertise to her new role at Alvotech. Her background includes a significant tenure as Alvogen's Chief Quality Officer, where she was instrumental in regulatory compliance and Good Manufacturing Practice (GMP). She holds a Master of Science in Regulatory Affairs and Quality Assurance from Temple University and a Bachelor of Science in Applied Biology from Georgia Institute of Technology.
Robert Wessman, Chairman and CEO of Alvotech, expressed gratitude to Sandra Casaca for her contributions, particularly her leadership during the recent FDA facility inspection. This inspection was pivotal for the approval of Alvotech's interchangeable high-concentration biosimilar to Humira in the U.S. Wessman is confident in Siniscalchi's ability to lead the quality team effectively, citing her extensive experience and familiarity with the company's operations.
Alvotech focuses on developing and manufacturing biosimilar medicines, aiming to offer high-quality and cost-effective alternatives to patients globally. The company boasts a pipeline of eight disclosed biosimilar candidates targeting various conditions, including autoimmune disorders, eye disorders, osteoporosis, respiratory diseases, and cancer.
The company has established a network of strategic commercial partnerships to extend its global reach, collaborating with entities across the United States, Europe, Japan, China, and other Asian countries, as well as significant portions of South America, Africa, and the Middle East.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.